Frederick Pei Li
Pour les articles homonymes, voir Li.
Frederick Pei Li, né le à Canton en Chine, et mort le [1], est un médecin américain.
| Naissance | |
|---|---|
| Décès | |
| Nom dans la langue maternelle |
李沛 |
| Nationalité | |
| Formation | |
| Activités |
| A travaillé pour | |
|---|---|
| Distinction |
Prix Charles-Mott (en) () |
Cette section ou cet article est une traduction incomplète ().
Vous pouvez modifier la page pour effectuer la traduction.
Biographie modifier
Né en Chine, Frederick Pei Li est arrivé à New York où ses parents avaient un restaurant chinois. Il a reçu un Bachelor of Arts en physique à l'université de New York et le titre de docteur en médecine à l'université de Rochester, puis un Master's degree en démographie à l'université de Georgetown. En 1967, il rejoint la section épidémiologie du National Cancer Institute. Il y a travaillé 24 ans durant, le plus souvent au centre « de terrain » du NCI au Dana–Farber Cancer Institute (en) à Boston. En 1991, il devient le chef du département d'épidémiologie et de contrôle du cancer au « Dana-Farber » (Dana-Farber's Division of Cancer Epidemiology and Control).
Frederick Pei Li est professeur d'épidémiologie clinique du cancer à la faculté de médecine d'Harvard, professeur de médecine de cette même école et professeur au Harry and Elsa Jiler American Cancer Society Clinical Research.
En 1996, il a été nommé par le président Bill Clinton au NCI's National Cancer Advisory Board.
Texte anglais à traduire :
This is Li's presentation of himself and his work:
Research Interests : Molecular Epidemiology of Hereditary Cancers
Recent data have established that the basic molecular defects in cancer are genetic changes that result in loss of normal cellular control mechanisms. Some of these mutations can be inherited through the germline. "I have been studying inherited susceptibility of cancer through affected families. The goal is to identify genes that are involved in cancer development".
"I was attracted to studies of cancer families because epidemiological studies show that virtually all cancers manifest a tendency to aggregate in families. Close relatives of a cancer patient are at increased risk of that neoplasm, and perhaps other forms of cancer. The excess site-specific cancer risk is exceptionally high for carriers of certain cancer genes, in whom the attack rate can approach 100 percent. In candidate cancer families, the possibility that clustering is on the basis of chance must be excluded through epidemiological studies that establish the presence of an excess cancer risk. Predisposed families are candidates for laboratory studies to identify the inherited susceptibility factors. These investigations have lead to the identification and isolation of human cancer genes, the tumor suppressor genes. These cancer genes are among more than 200 single-gene traits associated with the development of cancer. Approximately a dozen inherited susceptibility genes have been definitively identified, and many more are being sought. From studies of retinoblastoma and other rare cancers, important new information was generated about the fundamental biology of cancers that arise in many patients. Isolation of an inherited cancer susceptibility gene provides opportunities for presymptomatic testing of at-risk relatives. However, testing of healthy individuals also raise important issues regarding informed consent, confidentiality and potential for adverse psychological, social and economic effects."
"My colleagues and I are using families with inherited mutations in the p53 gene, which predisposes to breast cancer and diverse childhood cancers, as a model for developing a genetic testing program".
Il a donné son nom au syndrome de Li-Fraumeni.
